Senti Biosciences Soars Over 400% on Promising Phase 1 Data for Off-the-Shelf CAR-NK Therapy SENTI-202 in Relapsed/Refractory AML

Dec 04, 2024 11:20 CST Updated 11:20

Senti Biosciences

Gene and Cell Therapy Developer

Recently, Senti Biosciences, Inc. (NASDAQ: SNTI) announced preliminary data from a Phase I clinical trial targeting relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The therapy, named SENTI-202, is an off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate hematologic malignancies expressing CD33 and/or FLT3 while sparing healthy bone marrow cells.

As of the data cutoff for this cohort, among the three AML patients treated at the lowest dose level (1 billion CAR+ NK cells per dose), two achieved complete remission (CR), with both patients testing negative for minimal residual disease (MRD), indicating no detectable cancer cells in their bone marrow samples. At the time of data analysis summary, these two patients had maintained a disease-free status for over 4 months and 3 months, respectively. All three patients generally tolerated SENTI-202 well, with an adverse event profile consistent with AML patients undergoing conventional chemotherapy. Additionally, the transgene of SENTI-202 was detectable in the peripheral blood of all three patients across all treatment cycles, exhibiting pharmacokinetic characteristics consistent with other experimental CAR-NK therapies.

Currently, this Phase I clinical trial is planning to conduct dose-escalation testing with a higher dose of 1.5 billion CAR+ NK cells per dose, with more data on safety and efficacy, including initial durability data, expected to be reported by 2025.

Impacted by the aforementioned positive clinical data, the share price of Senti Biosciences soared on December 2, 2024, with a trading volume reaching 73.4 million shares, far exceeding the average trading volume of 17,810 shares.The stock price surged by 439%., closing price was $11.66 per share.

About SENTI-202

SENTI-202 is a universal CAR-NK cell therapy candidate product designed using the synthetic biology technology platform Gene Circuits. It aims to selectively target and eliminate hematologic malignancies expressing CD33 and/or FLT3, such as AML and myelodysplastic syndrome (MDS), while preserving healthy bone marrow cells. It consists of three main components: an activating CAR for recognizing CD33 and FLT3, an inhibitory CAR for protecting healthy cells, and a calibrated IL-15 release mechanism to enhance cell persistence and activity.

E.N.D

Previous article recommendations:

FDA Approves RegeneCyte™ Umbilical Cord Blood Stem Cell Therapy for Market Release

First Case in China! Bioraygene Gene Therapy Helps Foreign Patient with Sickle Cell Disease Gain New Life!

Annual Output Value Reaches 2.8 Billion Yuan, Covering 30,000 Square Meters: A GMP Production Base for Nucleic Acid Drugs in China Begins Operations

A Cell Therapy Company in China Goes Public in Hong Kong

IMMUNOON Successfully Raised HKD 2.3 Billion in Financing

Four Departments Including the National Health Commission and the Ministry of Commerce Issue Document: Nine Provinces/Cities to Pilot Allowing Wholly Foreign-Owned Hospitals, but with Restrictions on Experimental Treatments Involving New Technologies like Tumor Cell Therapy

First Stem Cell Therapy Adverse Reaction Liability Insurance Launched in Sichuan

Hanyuan Biotech and Hanxin Biotech Reach Strategic Cooperation to Jointly Advance the Innovation and Application of Nucleic Acid Drugs

Huaxi Licheng Hospital Officially Opens, Featuring "Stem Cell Therapy" and Other Specialized Treatment Models

$1.5 Billion! Roche Acquires a Cell and Gene Therapy Company

Shanghai Releases "Science and Technology Innovation Action Plan" Cell and Gene Therapy Special Project Approval Notice

Phase I Clinical Data of iPSC-derived CAR-T Cell Therapy for Lupus Erythematosus Released

George Church's Team Develops mRNA Anti-Aging Therapy, Turning Back the Clock on Skin

Focusing on the Cell and Gene Therapy Field, a Research and Production Base in China Completed and Commissioned

CSPC Initiates Phase I Clinical Trial of CAR-T Cell Therapy for Systemic Lupus Erythematosus

Ministry of Commerce: Forward-looking Layout of Key Industries such as Cell and Gene Therapy, Supporting Suzhou Industrial Park in Piloting Open Innovation for the Entire Biomedical Industry Chain

Breakthrough in Solid Tumors: Latest 'Nature' Publishes Clinical Trial Results of CAR-T Treating Deadly Brain Tumors

CDE Releases "Technical Guideline for Clinical Pharmacology Studies of Cell Therapy Products (Trial)"

A Biotech Company in Guangdong Officially Opens, Focusing on Cell and Gene Therapy Fields

Breaking AAV Payload Limits, "Science" Publishes Research on StitchR™ RNA Assembly Technology and Its Application in Treating Muscular Dystrophy

World’s First In Vivo CAR Gene Therapy Approved for Phase I Clinical Trial Completes First Patient Dosing

Total investment of approximately 3 billion yuan, construction area of 100,000 square meters, a cell therapy drug research and development and production base in China officially starts construction.

World's First TIL Cell Therapy Generates $640 Million in Half-Year Revenue, Expected to Exceed $1.1 Billion for the Full Year

Global First Stem Cell Therapy for Type 1 Diabetes Advances to Phase 3 Clinical Trials

Purchase Price Approximately 187 Million Yuan: Northeast Pharmaceutical to Officially Acquire 70% Stake in a Chinese Cell Therapy Company

Official Announcement! Stem Cell Exosomes Not Managed as Medical Devices

World's First! Bionovation Biotech's Non-Viral Targeted Integration PD1-CAR-T Therapy for Lupus Erythematosus Approved for Clinical Trials in China

Shanghai Releases Three-Year Action Plan, Continuously Supporting Innovation and R&D in Frontier Areas Such as Cell and Gene Therapy, Nucleic Acid Drugs, and Brain-Computer Interfaces (with Policy Interpretation)

Disclaimer: The content is sourced from the WeChat Official Account "Cell Gene Therapy." This article aims to share knowledge, and all content is for reference only and does not constitute any advice.